{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T03:45:37Z","timestamp":1789962337550,"version":"4.0.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Malaria remains a major public health burden in Africa, particularly among children under five years of age. By consolidating findings across randomized controlled trials on the RTS,S and R21 malaria vaccines, this study seeks to provide an evidence based guide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review and meta-analysis of studies of randomized controlled trials evaluating the RTS,S and R21 malaria vaccines in African children under five. Data sources included PubMed, Scopus, and Embase. Primary outcomes were the vaccine efficacies against first\/only episodes of malaria, multiple episodes and severe malaria; and the incidence of severe adverse events following vaccination. Pooled effect estimates were calculated using random-effects models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eleven studies enrolling 27,178 participants (RTS,S: 21,589; R21: 5589) were included. For RTS,S, pooled efficacy against first clinical malaria episode was 32% (HR 0.68, 95% CI 0.61\u20130.76; I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090%), against multiple episodes was 29% (IRR 0.71, 95% CI 0.55\u20130.91; I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200911.3%), and against severe malaria was 17\u201322% (RR 0.78\u20130.83). The R21 vaccine demonstrated 68% efficacy against first episodes (HR 0.32, 95% CI 0.26\u20130.39) and 67% against multiple episodes (IRR 0.33, 95% CI 0.27\u20130.41) in a single phase 3 trial. Pooled SAE incidence was 11.2% (95% CI 6.6\u201318.6%; I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200996.2%) for RTS,S and 3% (95% CI 1\u20136%; I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200980.6%) for R21, with no vaccine-attributable deaths. Both vaccines showed acceptable reactogenicity profiles.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Both RTS,S and R21 vaccines demonstrate protective efficacy against clinical malaria in African children under five, with R21 showing higher efficacy in initial trials. RTS,S provides moderate, reproducible protection in clinical trials. Both vaccines have acceptable safety profiles, though continued pharmacovigilance is essential.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12936-026-05954-5","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T09:15:01Z","timestamp":1779873301000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of RTS, S and R21 malaria vaccines in children under five in Africa: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0502-0938","authenticated-orcid":false,"given":"Khulud Mahmood","family":"Nurani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2233-7371","authenticated-orcid":false,"given":"Najib","family":"Kadernani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2739-9535","authenticated-orcid":false,"given":"Emmanuel","family":"Korir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3778-960X","authenticated-orcid":false,"given":"Merna Akram","family":"Estreed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1794-2569","authenticated-orcid":false,"given":"Arkadeep","family":"Dhali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1611-2004","authenticated-orcid":false,"given":"Rugut","family":"Clinton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2395-5846","authenticated-orcid":false,"given":"Khalid","family":"Kadernani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6946-8857","authenticated-orcid":false,"given":"Vincent","family":"Kipkorir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7431-1310","authenticated-orcid":false,"given":"Pius","family":"Omullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3385-0821","authenticated-orcid":false,"given":"Moses","family":"Masika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"5954_CR1","unstructured":"World Health Organization. World malaria report 2025: Addressing the threat of antimalarial drug resistance 2025."},{"key":"5954_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12936-022-04052-6","volume":"21","author":"S Nalinya","year":"2022","unstructured":"Nalinya S, Musoke D, Deane K. Malaria prevention interventions beyond long-lasting insecticidal nets and indoor residual spraying in low- and middle-income countries: a scoping review. Malar J. 2022;21:31. https:\/\/doi.org\/10.1186\/s12936-022-04052-6.","journal-title":"Malar J"},{"key":"5954_CR3","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1093\/infdis\/jiaa582","volume":"223","author":"MH Rodriguez","year":"2021","unstructured":"Rodriguez MH. Residual malaria: limitations of current vector control strategies to eliminate transmission in residual foci. J Infect Dis. 2021;223:S55-60. https:\/\/doi.org\/10.1093\/infdis\/jiaa582.","journal-title":"J Infect Dis"},{"key":"5954_CR4","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1080\/21645515.2019.1669415","volume":"16","author":"MB Laurens","year":"2020","unstructured":"Laurens MB. RTS,S\/AS01 vaccine (MosquirixTM): an overview. Hum Vaccin Immunother. 2020;16:480\u20139. https:\/\/doi.org\/10.1080\/21645515.2019.1669415.","journal-title":"Hum Vaccin Immunother"},{"key":"5954_CR5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12936-020-3141-z","volume":"19","author":"J Molina-Franky","year":"2020","unstructured":"Molina-Franky J, Cuy-Chaparro L, Camargo A, Reyes C, G\u00f3mez M, Salamanca DR, et al. Plasmodium falciparum pre-erythrocytic stage vaccine development. Malar J. 2020;19:56. https:\/\/doi.org\/10.1186\/s12936-020-3141-z.","journal-title":"Malar J"},{"key":"5954_CR6","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/S0140-6736(21)00943-0","volume":"397","author":"MS Datoo","year":"2021","unstructured":"Datoo MS, Natama MH, Som\u00e9 A, Traor\u00e9 O, Rouamba T, Bellamy D, et al. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. The Lancet. 2021;397:1809\u201318. https:\/\/doi.org\/10.1016\/S0140-6736(21)00943-0.","journal-title":"The Lancet"},{"key":"5954_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12936-024-04846-w","volume":"23","author":"N Aderinto","year":"2024","unstructured":"Aderinto N, Olatunji G, Kokori E, Sikirullahi S, Aboje JE, Ojabo RE. A perspective on Oxford\u2019s R21\/Matrix-M\u2122 malaria vaccine and the future of global eradication efforts. Malar J. 2024;23:16. https:\/\/doi.org\/10.1186\/s12936-024-04846-w.","journal-title":"Malar J"},{"key":"5954_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"2021","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"5954_CR9","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev. 2016;5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst Rev"},{"key":"5954_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1475-2875-12-11","volume":"12","author":"S Abdulla","year":"2013","unstructured":"Abdulla S, Salim N, Machera F, Kamata R, Juma O, Shomari M, et al. Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S\/AS02D malaria vaccine in infants living in a malaria-endemic region. Malar J. 2013;12:11. https:\/\/doi.org\/10.1186\/1475-2875-12-11.","journal-title":"Malar J"},{"key":"5954_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013838","volume":"5","author":"P Aide","year":"2010","unstructured":"Aide P, Aponte JJ, Renom M, Nhampossa T, Sacarlal J, Mandomando I, et al. Safety, immunogenicity and duration of protection of the RTS,S\/AS02D malaria vaccine: one year follow-up of a randomized controlled phase I\/IIb trial. PLoS ONE. 2010;5:e13838. https:\/\/doi.org\/10.1371\/journal.pone.0013838.","journal-title":"PLoS ONE"},{"key":"5954_CR12","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S1473-3099(11)70100-1","volume":"11","author":"KP Asante","year":"2011","unstructured":"Asante KP, Abdulla S, Agnandji S, Lyimo J, Vekemans J, Soulanoudjingar S, et al. Safety and efficacy of the RTS,S\/AS01 E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Lancet Infect Dis. 2011;11:741\u20139. https:\/\/doi.org\/10.1016\/S1473-3099(11)70100-1.","journal-title":"Lancet Infect Dis"},{"key":"5954_CR13","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/S1473-3099(22)00442-X","volume":"22","author":"MS Datoo","year":"2022","unstructured":"Datoo MS, Natama HM, Som\u00e9 A, Bellamy D, Traor\u00e9 O, Rouamba T, et al. Efficacy and immunogenicity of R21\/Matrix-M vaccine against clinical malaria after 2 years\u2019 follow-up in children in Burkina Faso: a phase 1\/2b randomised controlled trial. Lancet Infect Dis. 2022;22:1728\u201336. https:\/\/doi.org\/10.1016\/S1473-3099(22)00442-X.","journal-title":"Lancet Infect Dis"},{"key":"5954_CR14","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(23)02511-4","volume":"403","author":"MS Datoo","year":"2024","unstructured":"Datoo MS, Dicko A, Tinto H, Ou\u00e9draogo J-B, Hamaluba M, Olotu A, et al. Safety and efficacy of malaria vaccine candidate R21\/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. The Lancet. 2024;403:533\u201344. https:\/\/doi.org\/10.1016\/S0140-6736(23)02511-4.","journal-title":"The Lancet"},{"key":"5954_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0014090","volume":"5","author":"J Lusingu","year":"2010","unstructured":"Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, Olivier A, et al. Safety of the malaria vaccine candidate, RTS,S\/AS01E in 5 to 17 month old Kenyan and Tanzanian children. PLoS ONE. 2010;5:e14090. https:\/\/doi.org\/10.1371\/journal.pone.0014090.","journal-title":"PLoS ONE"},{"key":"5954_CR16","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/S1473-3099(10)70262-0","volume":"11","author":"A Olotu","year":"2011","unstructured":"Olotu A, Lusingu J, Leach A, Lievens M, Vekemans J, Msham S, et al. Efficacy of RTS,S\/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5\u201317 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis. 2011;11:102\u20139. https:\/\/doi.org\/10.1016\/S1473-3099(10)70262-0.","journal-title":"Lancet Infect Dis"},{"key":"5954_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007302","volume":"4","author":"S Owusu-Agyei","year":"2009","unstructured":"Owusu-Agyei S, Ansong D, Asante K, Kwarteng Owusu S, Owusu R, Wireko Brobby NA, et al. Randomized controlled trial of RTS,S\/AS02D and RTS,S\/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children. PLoS ONE. 2009;4:e7302. https:\/\/doi.org\/10.1371\/journal.pone.0007302.","journal-title":"PLoS ONE"},{"key":"5954_CR18","doi-asserted-by":"publisher","unstructured":"The RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 2015;386:31\u201345. https:\/\/doi.org\/10.1016\/S0140-6736(15)60721-8.","DOI":"10.1016\/S0140-6736(15)60721-8"},{"key":"5954_CR19","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1086\/600119","volume":"200","author":"J Sacarlal","year":"2009","unstructured":"Sacarlal J, Aide P, Aponte JJ, Renom M, Leach A, Mandomando I, et al. Long-term safety and efficacy of the RTS,S\/AS02A malaria vaccine in mozambican children. J INFECT DIS. 2009;200:329\u201336. https:\/\/doi.org\/10.1086\/600119.","journal-title":"J INFECT DIS"},{"key":"5954_CR20","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S1473-3099(22)00273-0","volume":"22","author":"AM Samuels","year":"2022","unstructured":"Samuels AM, Ansong D, Kariuki SK, Adjei S, Bollaerts A, Ockenhouse C, et al. Efficacy of RTS,S\/AS01E malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5\u201317 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial. Lancet Infect Dis. 2022;22:1329\u201342. https:\/\/doi.org\/10.1016\/S1473-3099(22)00273-0.","journal-title":"Lancet Infect Dis"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-026-05954-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-026-05954-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-026-05954-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T23:14:09Z","timestamp":1784848449000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12936-026-05954-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5954"],"URL":"https:\/\/doi.org\/10.1186\/s12936-026-05954-5","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"26 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"269"}}